Martin Šimkovič

15PUBLICATIONS

90CO-AUTHORS

Cancer therapy (excl. chemotherapy and radiation therapy)Central and Eastern European languages (incl. Russian)Predictive and prognostic markersCellular immunologyComputational linguistics

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (15)

Sort by Publication Date:

|May 12, 2026

Comparable outcomes of BTK inhibitors and fixed-duration venetoclax plus rituximab in second-line treatment of chronic lymphocytic leukaemia: a real-world analysis by the Czech CLL study group.

|Oct 24, 2025

Central nervous system involvement in CLL: an international retrospective study by ERIC, the European Research Initiative on CLL.

Thomas Chatzikonstantinou, Mariia Mikhaleva, Christian Brieghel

|Aug 19, 2025

Zanubrutinib for the treatment of patients with del(17p) and/or TP53 CLL/SLL: analysis across clinical studies.

Constantine S Tam, Mary Ann Anderson, Martin Šimkovič

|Feb 20, 2025

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.

Jennifer R Brown, John F Seymour, Wojciech Jurczak

|Dec 08, 2024

Zanubrutinib Versus Bendamustine and Rituximab in Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Median 5-Year Follow-Up of SEQUOIA.

Mazyar Shadman, Talha Munir, Tadeusz Robak

|Sep 24, 2024

Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE.

Jennifer R Brown, Barbara Eichhorst, Nicole Lamanna

Pageof 3

Frequent Collaborators

Jennifer R Brown

Lukáš Smolej

Pavel Vodárek

Tadeusz Robak

Dominika Écsiová

Mazyar Shadman

Pavel Žák

Constantine S Tam

Paolo Ghia

Vladimíra Řezáčová

Frequent Collaborators

Jennifer R Brown

Lukáš Smolej

Pavel Vodárek

Tadeusz Robak